ATE423134T1 - Verbesserte sezernierung von neublastin - Google Patents

Verbesserte sezernierung von neublastin

Info

Publication number
ATE423134T1
ATE423134T1 AT04736510T AT04736510T ATE423134T1 AT E423134 T1 ATE423134 T1 AT E423134T1 AT 04736510 T AT04736510 T AT 04736510T AT 04736510 T AT04736510 T AT 04736510T AT E423134 T1 ATE423134 T1 AT E423134T1
Authority
AT
Austria
Prior art keywords
neublastin
construct
region
nervous system
nucleotide sequence
Prior art date
Application number
AT04736510T
Other languages
English (en)
Inventor
Lars Wahlberg
Mette Groenborg
Philip Kusk
Jens Tornoee
Nels Pederson
William Sisk
Original Assignee
Nsgene As
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nsgene As, Biogen Idec Inc filed Critical Nsgene As
Application granted granted Critical
Publication of ATE423134T1 publication Critical patent/ATE423134T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04736510T 2003-06-10 2004-06-10 Verbesserte sezernierung von neublastin ATE423134T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300861 2003-06-10
US50748303P 2003-10-02 2003-10-02

Publications (1)

Publication Number Publication Date
ATE423134T1 true ATE423134T1 (de) 2009-03-15

Family

ID=34485959

Family Applications (2)

Application Number Title Priority Date Filing Date
AT09153016T ATE478092T1 (de) 2003-06-10 2004-06-10 Verbesserte sekretion von neublastin
AT04736510T ATE423134T1 (de) 2003-06-10 2004-06-10 Verbesserte sezernierung von neublastin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT09153016T ATE478092T1 (de) 2003-06-10 2004-06-10 Verbesserte sekretion von neublastin

Country Status (17)

Country Link
US (1) US7601518B2 (de)
EP (2) EP1636260B1 (de)
JP (1) JP5623685B2 (de)
KR (1) KR20060031618A (de)
CN (1) CN100475846C (de)
AT (2) ATE478092T1 (de)
AU (1) AU2004245175C1 (de)
BR (1) BRPI0411243A (de)
CA (1) CA2527914C (de)
DE (2) DE602004028769D1 (de)
DK (2) DK1636260T3 (de)
ES (2) ES2353457T3 (de)
HK (1) HK1082752A1 (de)
IL (1) IL172270A (de)
NZ (1) NZ544263A (de)
RU (1) RU2005138368A (de)
WO (1) WO2004108760A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
JP4742030B2 (ja) 2003-04-18 2011-08-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド ポリマーが結合したグリコシル化ニューブラスチン
ES2521682T3 (es) 2003-05-21 2014-11-13 Genzyme Corporation Procedimientos para producir preparaciones de viriones de AAV recombinantes sustancialmente exentas de cápsidas vacías
NZ544263A (en) 2003-06-10 2009-04-30 Nsgene As Improved secretion of neublastin
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
US20060239966A1 (en) * 2003-10-20 2006-10-26 Tornoee Jens In vivo gene therapy of parkinson's disease
BRPI0514534A (pt) * 2004-08-19 2008-06-17 Biogen Idec Inc variantes de neublastina
KR101241551B1 (ko) 2004-08-19 2013-03-11 바이오겐 아이덱 엠에이 인코포레이티드 전환 성장 인자 베타 패밀리 단백질의 리폴딩
ES2864039T3 (es) 2005-05-20 2021-10-13 Lonza Biologics Plc Expresión de alto nivel de un anticuerpo recombinante en una célula huésped de mamífero
US20080260702A1 (en) * 2005-10-11 2008-10-23 Jesper Roland Jorgensen Treatment of Retinopathies Using Gfra3 Agonists
ES2406716T3 (es) * 2005-12-30 2013-06-07 Neurotech Usa, Inc. Dispositivo micronizado para el suministro de moléculas activas biológicamente y método de uso del mismo
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007103182A2 (en) * 2006-03-01 2007-09-13 Biogen Idec Ma Inc. Compostions and methods for administering gdnf ligand family proteins
EP2142205B1 (de) 2007-05-01 2014-04-02 Biogen Idec MA Inc. Neublastin Peptide für erhöhte Vaskularisierung im Gewebe mit reduzierter Durchblutung
EP2048237A1 (de) 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replikationsdefizienter Influenza-Virus zur Expression heterologer Sequenzen
RU2491344C2 (ru) * 2007-06-29 2013-08-27 Ф.Хоффманн-Ля Рош Аг Промотор
EP2205634A2 (de) * 2007-08-08 2010-07-14 Biogen Idec MA, Inc. Anti-neublastin-antikörper und anwendungen davon
JP6125751B2 (ja) * 2008-03-21 2017-05-10 ティシュージーン，インク． 椎間板変性症の治療
EP2281047B1 (de) * 2008-04-15 2020-04-08 Genzyme Corporation Verfahren zur herstellung des rod-derived cone viability-faktors (rdcvf)
WO2010083841A2 (en) * 2009-01-23 2010-07-29 Nsgene A/S Improved cell lines and their use in encapsulated cell biodelivery
EP2389191A2 (de) * 2009-01-23 2011-11-30 NsGene A/S Expression von neuropeptiden in säugetierzellen
EP2550362B1 (de) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv-glycoproteine und rekombinante vektoren
RS57397B8 (sr) 2011-06-10 2020-01-31 Univ Oregon Health & Science Cmv glikoproteini i rekombinantni vektori
CN107530451A (zh) * 2015-05-07 2018-01-02 南佛罗里达大学 用于天使人综合征的基因治疗方法的修饰的ube3a基因
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
CA3015660A1 (en) * 2016-03-04 2017-09-08 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
CN108610398B (zh) * 2018-01-15 2020-08-11 武汉海特生物制药股份有限公司 一段功能序列及在分泌蛋白表达中的应用
EP3749754A4 (de) * 2018-02-08 2021-10-20 Applied Stemcell, Inc. Verfahren für das screening von varianten eines zielgens
CN114008191A (zh) * 2018-12-21 2022-02-01 格洛丽亚娜治疗公司 哺乳动物细胞培养物产生的神经胚素抗体

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
EP0228458B2 (de) 1985-07-05 1997-10-22 Whitehead Institute For Biomedical Research Expression von fremdem genetischem material in epithelzellen
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
EP0378576B1 (de) 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduktionsveränderte fibroblasten und ihre anwendung
US5487739A (en) 1987-11-17 1996-01-30 Brown University Research Foundation Implantable therapy systems and methods
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5156844A (en) 1987-11-17 1992-10-20 Brown University Research Foundation Neurological therapy system
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
JP2791418B2 (ja) * 1987-12-02 1998-08-27 株式会社ミドリ十字 異種蛋白質の製造方法、組換えｄｎａ、形質転換体
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
IL95330A0 (en) * 1989-08-11 1991-06-30 Lilly Co Eli Expression of a functional insect specific toxin gene in mammalian cells
JP4215273B2 (ja) 1991-04-25 2009-01-28 ブラウン ユニヴァーシティ リサーチ ファンデーション 選択された治療物質放出用の移植可能で生体適合性の免疫遮断性ビークル
US7226758B1 (en) 1991-09-20 2007-06-05 Amgen Inc. Nucleic acids encoding glial cell line-derived neurotrophic factor (GDNF)
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
AU688776B2 (en) 1993-06-23 1998-03-19 Brown University Research Foundation Method and apparatus for sealing implantable, membrane encapsulation devices
AU7568094A (en) 1993-08-12 1995-03-14 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
AU710504B2 (en) 1994-03-15 1999-09-23 Brown University Research Foundation Polymeric gene delivery system
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US5677158A (en) 1995-06-07 1997-10-14 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5904144A (en) 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6027721A (en) 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
US6054142A (en) 1996-08-01 2000-04-25 Cyto Therapeutics, Inc. Biocompatible devices with foam scaffolds
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
JP2002502822A (ja) * 1998-02-10 2002-01-29 オレゴン ヘルス サイエンシーズ ユニバーシティー 骨芽細胞の前駆細胞による骨欠損の治療
US6303136B1 (en) 1998-04-13 2001-10-16 Neurotech S.A. Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane
US6683058B1 (en) 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
EP1080202B1 (de) 1998-05-27 2006-01-25 Avigen, Inc. Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
ES2275349T3 (es) 1998-07-14 2007-06-01 Janssen Pharmaceutica N.V. Factor de crecimiento neurotrofico.
US6284540B1 (en) 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
IL126562A0 (en) * 1998-10-14 1999-08-17 Interpharm Lab Ltd Expression and secretion of icil-1 receptor antagonist type ii
US6361741B1 (en) 1999-02-01 2002-03-26 Alcoa Inc. Brazeable 6XXX alloy with B-rated or better machinability
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
US6361771B1 (en) 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
AU1997501A (en) 1999-10-29 2001-05-08 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Use of GDNF for treating corneal defects
US6866851B1 (en) 1999-12-28 2005-03-15 Washington University GFRα1-RET specific agonists and methods therefor
EP1301214A2 (de) 2000-05-26 2003-04-16 Chiron Corporation Verfahren zur transduktion von neuronalen zellen unter verwendung von lentivirusvektoren
GB0018876D0 (en) * 2000-08-01 2000-09-20 Applied Research Systems Method of producing polypeptides
JP2005502582A (ja) * 2000-12-22 2005-01-27 ジェネンテック， インコーポレイテッド Ｇｄｎｆリガンドファミリーのメンバーである、アルテミンの新たな使用
BR0206852A (pt) 2001-02-01 2005-05-03 Biogen Inc Conjugados de polìmero de neublastina e métodos para uso dos mesmos
EP1395279B1 (de) * 2001-03-28 2011-10-05 Biogen Idec MA Inc. Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen
JP4742030B2 (ja) 2003-04-18 2011-08-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド ポリマーが結合したグリコシル化ニューブラスチン
NZ544263A (en) 2003-06-10 2009-04-30 Nsgene As Improved secretion of neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
MXPA06004329A (es) 2003-10-20 2006-06-05 Nsgene As Terapia genica in vivo de enfermedad de parkinson.

Also Published As

Publication number Publication date
DE602004019524D1 (de) 2009-04-02
IL172270A (en) 2015-04-30
WO2004108760A3 (en) 2005-04-07
EP1636260A2 (de) 2006-03-22
CA2527914A1 (en) 2004-12-16
HK1082752A1 (en) 2006-06-16
RU2005138368A (ru) 2006-07-27
KR20060031618A (ko) 2006-04-12
WO2004108760A2 (en) 2004-12-16
DK2058329T3 (da) 2010-12-06
NZ544263A (en) 2009-04-30
EP2058329B1 (de) 2010-08-18
AU2004245175B2 (en) 2009-10-15
AU2004245175A1 (en) 2004-12-16
CN100475846C (zh) 2009-04-08
DK1636260T3 (da) 2009-06-22
ATE478092T1 (de) 2010-09-15
JP5623685B2 (ja) 2014-11-12
EP2058329A1 (de) 2009-05-13
EP1636260B1 (de) 2009-02-18
ES2323066T3 (es) 2009-07-06
ES2353457T3 (es) 2011-03-02
US7601518B2 (en) 2009-10-13
IL172270A0 (en) 2006-04-10
DE602004028769D1 (de) 2010-09-30
JP2007535898A (ja) 2007-12-13
CN1835971A (zh) 2006-09-20
CA2527914C (en) 2014-10-28
US20050089960A1 (en) 2005-04-28
AU2004245175C1 (en) 2010-03-18
BRPI0411243A (pt) 2006-07-11

Similar Documents

Publication Publication Date Title
ATE423134T1 (de) Verbesserte sezernierung von neublastin
WO2004067706A3 (en) Production of multimeric proteins
ATE414775T1 (de) Polypeptide mit prolyldipeptidylaminopeptidase- aktivität und dafür kodierende nukleinsäuren
ATE352626T1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
DE69738483D1 (de) Polypeptide mit phytase-aktivität und sie kodierende nukleinsäuren
ATE489458T1 (de) Detoxifizym mit aktivität zur transformation von aflatoxin sowie das dafür codierende gen
ATE319818T1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
ATE290591T1 (de) Für adseverin kodierendes gen
ATE469217T1 (de) Den phosphorsäure-metabolismus, den kalzium- metabolismus, verkalkung und den vitamin d- metabolismus kontrollierende polypeptide sowie für diese kodierende dna-moleküle
DE60043428D1 (de) POLYPEPTIDE MIT VERZWEIGUNGSENZYM-AKTIVITäT UND FüR DIESE KODIERENDE NUKLEINSäUREN
ATE536409T1 (de) Unkrautbekämpfungsstoffwechselproteine, gene dafür und ihre verwendung
ATE358725T1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
CA2461443A1 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
WO2006042719A3 (de) Polypeptid mit phytaseaktivität und dieses codierende nucleotidsequenz
WO2005067410A3 (en) Synthetic nucleic acids from aquatic species
DE60330579D1 (de) Mikrobielle trypsinvarianten mit chymotrypsinaktivität und diese codierende nukleinsäuren
AR025482A1 (es) Secuencia de adn que codifica una proteina capaz de ligarse a traf; vector que comprende dicha secuencia; celulas huespedes transformadas con dicho vector;proteinas iren codificadas por dicha secuencia; metodo para producir dicha proteina; anticuerpos especificos para dichas proteinas; metodo para m
ATE474916T1 (de) Protease, für die protease codierende dna und verfahren zur herstellung der protease
KR880701073A (ko) 제조합 dna 기법에 의해 생성된 민악티빈
ATE317896T1 (de) Polypeptide mit glucanotransferase aktivität und dafür kodierende nukleinsäuren
DE602004019556D1 (de) Neues plexin-polypeptid, dieses codierende dna und verwendung davon
DE60026569D1 (de) Zusammensetzungen auf der basis von gfr-alpha-4 und deren anwendungen
EA200200286A1 (ru) Ген prv-1 и его применение
ATE489463T1 (de) Polypeptid mit einer delta-5-fettsäure- desaturierungsaktivität, für das polypeptid codierendes polynukleotid und verwendung davon.
AU7871101A (en) Nucleic acids and proteins showing increased expression dose under salt stress

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties